Start-up will focus on medicines for neural circuit dysfunction
Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference. The company’s approach combines adeno-associated viruses (AAV) in human neural circuits with tuneable conditionally-activated ion channels. This corrects dysfunctional neural excitation. Sania’s technology… Read More